

別紙4  
書籍

## 研究成果の刊行に関する一覧表

著者氏名	論文タイトル名	書籍全体の 編集者名	書 籍 名	出版社名	出版地	出版年	ページ
鈴木 文孝	NS5A阻害剤	榎本 信幸	HEPATOLOGY PRACTICE V ol.3	文光堂	東京	2014	189-192
鈴木 文孝	C型慢性肝炎治療 のガイドライン(厚労省 研究班編)の概説	熊田 博光	C型肝炎治療 ～DAA s で広 がる治療対 象～	(株)医薬 ジャーナル 社	東京	2014	55-62
鈴木 文孝	DAA sによるIFNフリー 療法(IFN free regi men)	熊田 博光	C型肝炎治療 ～DAA s で広 がる治療対 象～	(株)医薬 ジャーナル 社	東京	2014	108-119
馬渡 誠一、宇都 浩文、井戸 章 雄	HCVのウイルス学 的特徴	熊田博光、 茶山一彰、 豊田成司	C型肝炎治療	医薬ジャ ーナル	東京	2014	22-31
荒井 邦明、 金子 周一	肝臓病学 C型肝炎治療の転 換期		臨床医学の 展望2014	日本医事 新報	東京	2014	2-9

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Suzuki F, Toyota J, Ikeda K, Chayama K, Mochida S, Hayashi N, Ishikawa H, Miyagoshi H, Wenhua Hu, Fiona McPhee, Eric A Hughes, Kumada H	A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection.	Antiviral Therapy	19	491-499	2014
Suzuki F, Hosaka T, Suzuki Y, Akuta N, Sezaki H, Hara T, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M,	Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine. J Gastroenterol.	J Gastroenterol	49	1094-1104	2014

Watahiki S, Mineta R, Kumada H					
Hara T, <u>Suzuki F</u> , Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Kumada H	Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide-naive chronic hepatitis B patients.	J Viral Hepat	21	802-808	2014
<u>Suzuki F</u> , Akuta N, Suzuki Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, I keda K, Kobayashi M, Watahiki S, Mineta R, S uzuki Y, Kumada H	Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.	Drug Des Devel	8	869-873	2014
Ikeda K, Kawamura Y, Kobayashi M, Fukushima T, Sezaki H, Hosaka T, Akuta N, Saitoh S, <u>Suzuki F</u> , Suzuki Y, Arase Y, Kumada H	Prevention of disease progression with anti-inflammatory therapy in patients with HCV-related cirrhosis: A Markov model.	Oncology	86	295-302	2014
Akuta N, <u>Suzuki F</u> , Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kumada H	Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in HCV genotype 1b.	J Med Virol	86	1314-1322	2014
Akuta N, <u>Suzuki F</u> , Fukushima T, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H	Utility of Detection of Telaprevir-Resistant Variants for Prediction of Efficacy of Treatment of Hepatitis C Virus Genotype 1 Infection.	JCM	52	193-200	2014
Akuta N, <u>Suzuki F</u> , Kobayashi M, Hara T, Sezaki H, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kumada H	Correlation Between Hepatitis B Virus Surface Antigen Level and Alpha-Fetoprotein in Patients Free of Hepatocellular Carcinoma or Severe Hepatitis.	J Med Virol	86	131-138	2014
Arase Y, Kobayashi M, Kawamura Y, <u>Suzuki F</u> , Suzuki Y, Akuta N, Kobayashi M, Sezaki H, Saitoh S, Hosaka T, Ikeda K, Kumada H, Kobayashi T	Impact of Virus Clearance for the Development of Hemorrhagic Stroke in Chronic Hepatitis C.	J Med Virol	86	169-175	2014

Tanaka M, <u>Suzuki F</u> , Seko Y, Hara T, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H	Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B.	J Gastroenterol	49	470-480	2014
Kobayashi M, Hosaka T, <u>Suzuki F</u> , Akuta N, Sezaki H, Suzuki Y, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H	Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up.	J Gastroenterol	49	538-546	2014
Kawakami Y, <u>Suzuki F</u> , Karino Y, Toyota J, Kumada H, Chayama K	Telaprevir is effective given every 12 h at 750mg with pegylated interferon- $\alpha$ 2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT.	Antiviral Therapy	19	277-285	2014
Hosaka T, <u>Suzuki F</u> , Kobayashi M, Fukushima T, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H	HLA-DP genes polymorphisms associate with hepatitis B surface antigen kinetics and seroclearance during nucleoside analogue therapy.	Liver Int		Epub ahead of print	2014
Kawamura Y, Ikeda K, Fukushima T, Hara T, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, <u>Suzuki F</u> , Suzuki Y, Kumada H	Potential of a no-touch pincer ablation procedure for small hepatocellular carcinoma that uses a multipolar radiofrequency ablation system: An experimental animal study.	Hepatol Res		Epub ahead of print	2014
Sezaki H, <u>Suzuki F</u> , Hosaka T, Akuta N, Fukushima T, Hara T, Kawamura Y, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H	Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patients.	Hepatol Res	44	163-171	2014
Kumada H, Sato K, Takehara T, Nakamura M, Ishigami M, Chayama K, Toyota J, <u>Suzuki F</u> , Nakayasu Y, Ochi M,	Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan.	Hepatol Res		Epub ahead of print.	2014

Yamada I, Okanoué T					
<u>Karino Y</u> , Toyota J, Ikeda K, Suzuki F, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Hernandez D, Yu F, McPhee F, Kumada H.	Telaprevir impairs renal function and increase blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C.	J Hepatol	21	341-347	2014
Tanaka T, Kasai H, Yamashita A, Okuyama-Dobashi K, Yasumoto J, <u>Maekawa S</u> , Enomoto N, Okamoto T, Matsura Y, Morimatsu M, Manabe N, Ochiai K, Yamashita K, Moriishi K.	Hallmarks of hepatitis C virus in equine hepatitis virus.	J Virol.	88(22)	13352-66.	2014
Tatsumi A, <u>Maekawa S</u> , Sato M, Komatsu N, Miura M, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Enomoto N.	Liver stiffness measurement for risk assessment of hepatocellular carcinoma.	Hepatol Res.		Epub ahead of print	2014
Miura M, <u>Maekawa S</u> , Sato M, Komatsu N, Tatsumi A, Takano S, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Enomoto N.	Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection.	Hepatol Res.		Epub ahead of print	2014
Komatsu N, Motosugi U, <u>Maekawa S</u> , Shindo K, Sakamoto M, Sato M, Tatsumi A, Miura M, Amemiya F, Nakayama Y, Inoue T, Fukasawa M, Uetake T, Ohtaka M, Sato T, Asahina Y, Kurosaki M, Izumi N, Ichikawa T, Araki T, Enomoto N.	Hepatocellular carcinoma risk assessment using gadoteric acid-enhanced hepatocyte phase magnetic resonance imaging.	Hepatol Res.	44(13)	1339-1346.	2014
<u>Maekawa S</u> , Enomoto N.	Once-daily simeprevir in combination with pegylated-interferon and ribavirin: a new horizon in the era of direct-acting antiviral agent therapy for chronic hepatitis C.	J Gastroenterol.	49(1)	163-4.	2014
Oda K, <u>Uto H</u> , Kumagai K, Ido A, Kusumoto K, Shimoda K, Hayashi K, Stuver SO, Tanaka Y, Nishida N, Tokunaga K, Tsubouchi H.	Impact of a single nucleotide polymorphism upstream of the IL28B gene in patients positive for anti-HCV antibody in an HCV hyperendemic area in Japan	J Med Virol.	86	1877-1885	2014

Tokunaga M, <u>Uto H</u> , Oda K, Tokunaga M, M awatari S, Kumagai K, Haraguchi K, Oketani M, Ido A, Ohnou N, Ut sunomiya A, Tsubouchi H	Influence of human T-lymphotro pic virus type 1 coinfection on t he development of hepatocellular carcinoma in patients with hepa titis C virus infection	J Gastroenterol	49	1567-1577	2014
Suzuki F, Hosaka T, Suzuki Y, Akuta N, <u>Sezaki H</u> , Hara T, Kawamura Y, Kobayashi M, Saitoh S Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H	Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine.J Gastroenterol.	J Gastroenterol	49	1094-1104	2014
Hara T, Suzuki F, Kawamura Y, <u>Sezaki H</u> , Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Kumada H	Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide-naive chronic hepatitis B patients.	J Viral Hepat	21	802-808	2014
Suzuki F, Akuta N, Suzuki Y, <u>Sezaki H</u> , Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Suzuki Y, Kumada H	Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.	Drug Des Devel	8	869-873	2014
Ikeda K, Kawamura Y, Kobayashi M, Fukushima T, <u>Sezaki H</u> , Hosaka T, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H	Prevention of disease progression with anti-inflammatory therapy in patients with HCV-related cirrhosis: A Markov model.	Oncology	86	295-302	2014
Akuta N, Suzuki F, <u>Sezaki H</u> , Suzuki Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kumada H	Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in HCV genotype 1b.	J Med Virol	86	1314-1322	2014
Akuta N, Suzuki F, Fukushima T, Kawamura Y, <u>Sezaki H</u> , Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H	Utility of Detection of Telaprevir-Resistant Variants for Prediction of Efficacy of Treatment of Hepatitis C Virus Genotype 1 Infection.	JCM	52	193-200	2014

Akuta N, Suzuki F, Kobayashi M, Hara T, <u>Sezaki H</u> , Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kumada H	Correlation Between Hepatitis B Virus Surface Antigen Level and Alpha-Fetoprotein in Patients Free of Hepatocellular Carcinoma or Severe Hepatitis.	J Med Virol	86	131-138	2014
Arase Y, Kobayashi M, Kawamura Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, <u>Sezaki H</u> , Saitoh S, Hosaka T, Ikeda K, Kumada H, Kobayashi T	Impact of Virus Clearance for the Development of Hemorrhagic Stroke in Chronic Hepatitis C.	J Med Virol	86	169-175	2014
Tanaka M, Suzuki F, Seko Y, Hara T, Kawamura Y, <u>Sezaki H</u> , Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H	Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B.	J Gastroenterol	49	470-480	2014
Kobayashi M, Hosaka T, Suzuki F, Akuta N, <u>Sezaki H</u> , Suzuki Y, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H	Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up.	J Gastroenterol	49	538-546	2014
Hosaka T, Suzuki F, Kobayashi M, Fukushima T, Kawamura Y, <u>Sezaki H</u> , Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H	HLA-DP genes polymorphisms associate with hepatitis B surface antigen kinetics and seroclearance during nucleoside analogue therapy.	Liver Int		Epub ahead of print	2014
Kawamura Y, Ikeda K, Fukushima T, Hara T, Hosaka T, Kobayashi M, Saitoh S, <u>Sezaki H</u> , Akuta N, Suzuki F, Suzuki Y, Kumada H	Potential of a no-touch pincer ablation procedure for small hepatocellular carcinoma that uses a multipolar radiofrequency ablation system: An experimental animal study.	Hepatol Res		Epub ahead of print	2014
<u>Sezaki H</u> , Suzuki F, Hosaka T, Akuta N, Fukushima T, Hara T, Kawamura Y, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H	Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patients.	Hepatol Res	44	163-171	2014

Takamura H, Nakanuma S, Hayashi H, Tajima H, Kakinoki K, Kitahara M, Sakai S, Makino I, Nakagawara H, Miyashita T, Okamoto K, Nakamura K, Oyama K, Inokuchi M, Ninomiya I, Kitagawa H, Fushida S, Fujimura T, Onishi I, Kayahara M, Tani T, <u>Arai K</u> , Yamashita T, Yamashita T, Kitamura H, Ikeda H, Kaneko S, Nakanuma Y, Matsui O, Ohta T.	Severe veno-occlusive disease/sinusoidal obstruction syndrome after deceased-donor and living-donor liver transplantation.	Transplant Proc.	46	3523-3535	2014
Terashima T, Yamashita T, <u>Arai K</u> , Sunagozaka H, Kitahara M, Nakagawa H, Kagaya T, Mizukoshi E, Honda M, Kaneko S.	Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib.	Hepatol Res.	44	1179-1185	2014
Terashima T, Yamashita T, Iida N, Yamashita T, Nakagawa H, <u>Arai K</u> , Kitamura K, Kagaya T, Sakai Y, Mizukoshi E, Honda M, Kaneko S	Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy.	Hepatol Res.		Epub ahead of print	2015
Yamada K, Mizukoshi E, Sunagozaka H, <u>Arai K</u> , Yamashita T, Takeshita Y, Misu H, Takamura T, Kitamura S, Zen Y, Nakanuma Y, Honda M, Kaneko S	Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis.	Liver Int.	35	582-590	2015
Nakamura M, Kondo H, Tanaka A, Komori A, Ito M, Yamamoto K, Ohira H, Zeniya M, Hashimoto E, Honda M, Kaneko S, Ueno Y, Kikuchi K, Shimoda S, Harada K, <u>Arai K</u> , Miyake Y, Abe M, Taniai M, Saibara T, Sakisaka S, Takikawa H, Onji M, Tsubouchi H,	Autoantibody status and histological variables influence biochemical response to treatment and long-term outcomes in Japanese patients with primary biliary cirrhosis.	Hepatol Res.		Epub ahead of print	2015

Nakanuma Y, Ishibashi H.					
Ooka Y, Chiba T, Ogasawara S, <u>Arai K</u> , Suzuki E, Tawada A, Yamashita T, Kanai F, Kaneko S, Yokosuka O	A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma.	Invest New Drugs.	32	723-728	2014
Terashima T, Mizukoshi E, <u>Arai K</u> , Yamashita T, Yoshida M, Ota H, Onishi I, Kayahara M, Ohtsubo K, Kagaya T, Honda M, Kaneko S.	P53, hTERT, WT-1, and VEGF R2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic ad enocarcinoma.	Cancer Immunol Immunother.		Epub ahead of print	2015
Takeshita Y, Takamura T, Honda M, Kita Y, Zen Y, Kato K, Misu H, Ota T, Nakamura M, Yamada K, Sunagozaka H, <u>Arai K</u> , Yamashita T, Mizukoshi E, Kaneko S.	The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial.	Diabetologia.	57	878-890	2014
Honda M, Shirasaki T, Shimakami T, Sakai A, Horii R, <u>Arai K</u> , Yamas hita T, Sakai Y, Yamas hita T, Okada H, Murai K, Nakamura M, Mizukoshi E, Kaneko S.	Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes.	Hepatology.	59	828-838	2014
Murakami E, Imamura M, Hayes CN, Abe H, <u>Hiraga N</u> , Honda Y, Ono A, Kosaka K, Kawaoka T, Tsuge M, Aikata H, Takahashi S, Miki D, Ochi H, Matsui H, Kanai A, Inaba T, McPhee F, Chayama K.	Ultradeep sequencing study of c hronic hepatitis C virus genotype 1 infection in patients treated with Daclatasvir, Peginterferon, a nd Ribavirin.	AAC	58	2105-2112	2014